Acta Cryst. (2003). E59, o38-o40  [ doi:10.1107/S160053680202247X ]

Cilansetron hydrochloride monohydrate, modification A (monoclinic)

P. G. Jones, H. Möller and E. Finner

Abstract: The absolute configuration of the monoclinic form of the title compound, (-)-5,6,9,10-tetrahydro-10-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-pyrido[3,2,1-jk]carbazol-11(8H)-one monohydrochloride monohydrate, C₂₀H₂₂N₃O⁺·Cl^-·H₂O, was established as R at the asymmetric carbon adjacent to the carbonyl function. This form [cf. the orthorhombic form; Jones et al. (2003). Acta Cryst. E59, o41-o43] involves two independent formula units with different ring conformations of the six-membered N-heterocycle, and somewhat different orientations of the imidazole ring. Each independent formula unit forms a helical hydrogen-bonded chain of alternating water and chloride residues; the cations are hydrogen bonded laterally to the chlorides.

Online 19 December 2002

Copyright © International Union of Crystallography
IUCr Webmaster